ABSTRACT
K
aposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), which is the most common malignancy in patients with AIDS (1) . Although the incidence of KS has significantly decreased since the introduction of effective antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1), it remains a common tumor in people with HIV/AIDS in the United States and is the most common tumor in sub-Saharan Africa, where the prevalence of both HIV and KSHV is high and access to HIV therapy remains limited (2) . KSHV has also been implicated as a causative agent of primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD), two relatively rare lymphoproliferative malignancies that arise in patients with AIDS (3) (4) (5) . Like all herpesviruses, the life cycle of KSHV has latent and lytic phases, both of which are implicated in the pathogenesis of KSHV-related malignancies. In KS and PELs, KSHV is predominantly latent and, as a result, refractory to current anti-herpes viral drug treatments that inhibit lytic replication. During viral latency, only a few viral genes are expressed. These viral products, including latency-associated nuclear antigen (LANA; ORF73), viral cyclin (vCyclin; ORF72), viral FLICE inhibitory protein (vFLIP; ORF71), kaposin (K12), and a cluster of 12 viral pre-microRNAs (miRNAs) maintain the persistence of the viral genome, drive cellular proliferation, and promote host cell survival (3) (4) (5) .
Although KSHV infection is necessary, it is not sufficient to trigger the development of KS, indicating the involvement of other essential cofactors. One potentially important cofactor in the pathogenesis of KS is HIV-1. Although HIV-1 infection is neither necessary nor sufficient for the development of KS, AIDSrelated KS (AIDS-KS) is more aggressive, disseminated, and resistant to treatment than other forms of KS, including those associ-ated with immunosuppression (6) . Immunosuppression clearly plays an important role in the development of AIDS-KS; however, it cannot explain the following problems. First, an elevated incidence of KS in patients with AIDS is observed compared to levels for other immunosuppressed patients. The incidence of KS in AIDS patients is 20,000 times higher versus 300 times higher in immunosuppressive patients than it is in the general population (7) . Second, KS frequently has early presentation prior to the onset of severe immunosuppression in patients with AIDS (8) . Moreover, KS is rapidly regressed in patients undergoing triple antiretroviral therapy before the complete restoration of the immune system (5) . Nevertheless, HIV-1 itself does not directly play an oncogenic role in AIDS-KS (9) . HIV-1 might contribute to KS development through several other mechanisms, such as induction of inflammatory cytokines and production of HIV-1-encoded regulatory proteins. For instance, inflammatory cytokines, such as gamma interferon (IFN-␥), oncostatin M (OSM), and hepatocyte growth factor/scatter factor (HGF/SF), produced in AIDS-KS patients not only promote the growth and proliferation of KS tumor cells in vitro and induce abnormal proliferation of endothelial cells, the likely precursor cell of the KS tumor cell, to acquire the typical characteristics of KS tumor cells (10) but also are partially responsible for KSHV reactivation (11) . HIV-1-encoded transactivator of transcription (Tat) induces growth, migration, invasion, and adhesion of endothelial cells and KS tumor cells (12, 13) . We and others have demonstrated that Tat not only triggers KSHV reactivation from latency (14, 15) but also accelerates tumor progression induced by KSHV-encoded oncoproteins, including the viral G protein-coupled receptor (vGPCR) and Kaposin A (16, 17) .
Besides Tat, negative factor (Nef) is another early HIV-1 accessory protein. It has a 27-kDa molecular mass and is produced from multiply spliced mRNAs, and it is required for efficient in vivo HIV replication and AIDS pathogenesis (18) . However, the mechanism whereby Nef favors the development of AIDS remains elusive. HIV-1-infected cells not only express large amounts of Nef in the cytoplasm and membrane but also release Nef into the extracellular environment (19) (20) (21) (22) (23) (24) . In HIV-infected patients, the concentration of Nef in the serum ranges from 1 to 10 ng/ml (22, 25) . Similar to Tat, circulating Nef can be taken up by B cells both in vivo and in vitro to regulate cellular functions, resulting in suppression of immunoglobulin class-switch DNA recombination via induction of IB␣ and SOCS proteins in AIDS patients (26) (27) (28) . Nef has been found to interact with numerous cellular kinases and intracellular signaling molecules, including p53, protein kinase C theta, phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and members of the Src family kinases, to generate a favorable cellular environment for infection (29) (30) (31) (32) (33) (34) (35) . Although it is described as an intracellular viral protein in the HIV-infected cells (36) , there is increasing evidence that extracellular Nef can also activate signaling pathways in the uninfected cells of different lineages (22, 26, (37) (38) (39) . Our recent study has provided the first line of laboratory evidence that exogenous Nef may also penetrate endothelial cells and synergize with KSHV viral interleukin-6 (vIL-6) to promote angiogenesis and tumorigenesis by activating AKT signaling (40) .
The discovery of miRNAs in herpesviruses has added another layer of complexity to our understanding of KSHV pathogenesis (41) . miRNAs are short noncoding RNA molecules that bind mainly to the 3= untranslated region (UTR) of target mRNA through an miRNA 5= "seed" region by partial sequence complementarity. This allows the recognition of multiple target mRNAs by a single miRNA as well as targeting of a single mRNA/protein by multiple miRNAs. As a result, miRNAs regulate the stability and repress protein translation of the target mRNAs (42) . KSHV encodes more than 2 dozen mature miRNAs derived from 12 premiRNAs with largely unknown functions (43) . These miRNAs are located in the latent genomic locus and are expressed during viral latency (44) . Cellular miRNAs have been linked to almost all known cellular processes, including proliferation, differentiation, and apoptosis. Both viral and cellular miRNAs are likely to play key roles in the latency, immune evasion, and pathogenesis of KSHV by directly regulating KSHV genes or indirectly regulating host genes (45) .
In this study, we examined the effect of HIV-1 Nef on the KSHV replication program. We found that both exogenous and intracellular Nef inhibited KSHV replication to enhance viral latency. Furthermore, we identified a cellular miRNA 1258 (hsa-miR-1258) which mediated Nef regulation of KSHV latency by directly targeting KSHV lytic switch protein RTA. This is believed to be the first study to report the involvement of Nef in KSHV latency, implying its important role in the pathogenesis of AIDS-related malignancies.
MATERIALS AND METHODS
Cell culture and transfection. The PEL cell lines BCBL-1, BC-3, and JSC-1 were maintained in RPMI 1640 containing 10% heat-inactivated fetal bovine serum (FBS), 2 mmol/liter of L-glutamine, 100 U/ml of penicillin, and 100 g/ml of streptomycin at 37°C in a humidified, 5% CO 2 atmosphere. Before transfection, BCBL-1 and BC-3 cells were incubated in serum-free RPMI 1640 medium in order to achieve maximum inducibility of KSHV replication as described previously (15) . HEK293, HEK293T, Vero/Bac36, and Vero/rKSHV.219 were maintained in Dulbecco's modified Eagle's medium plus 10% FBS. Vero/rKSHV.219, kindly provided by Jeffrey Vieira (Department of Laboratory Medicine, University of Washington, Seattle, WA), was a puromycin-resistant Vero cell line resulting from infection of a recombinant virus, rKSHV.219a, that expresses the green fluorescent protein (GFP) under the control of the cellular EF-1␣ promoter and the red fluorescent protein (RFP) under the control of the KSHV early lytic PAN promoter (46) . The expression of GFP indicates the presence of KSHV genome, while that of RFP signifies the entry into viral lytic replication. BCBL-1 and BC-3 cells were electroporated as described previously (47) (48) (49) (50) (51) . The efficiency of transfection in BCBL-1 or BC-3 was monitored by cotransfection with plasmid pEGFP-N2 (Clontech Laboratories, Palo Alto, CA), which contains the enhanced GFP gene fused to the cytomegalovirus immediate-early gene promoter. We routinely observed about 30% GFP-positive cells at 48 h after electroporation. Vero/Bac36, Vero/rKSHV.219, and 293T cells were transfected with Lipofectamine 2000 (Invitrogen, Inc., Carlsbad, CA) according to the manufacturer's instructions.
Plasmids. The Nef gene coding frame was PCR cloned from the template plasmid pCINL, a gift from John Guatelli (Division of Infectious Disease, University of California, San Diego, CA), into the EcoRI and SalI sites of the plasmid pCI-neo (Promega, Madison, WI) to create a recombinant plasmid, pNef. The Flag M2 epitope was fused in frame to the carboxyl-terminal end of the Nef open reading frame, and a Kozak sequence (GCCACC) was added upstream of the initiation codon ATG to enhance the expression of the target gene. The construct pGL3-Luc-RTA 3=UTR (RTA wild type) contains the full length of the KSHV RTA 3=UTR sequence downstream of the luciferase sequence in the pGL3-promoter plasmid. An RTA-expressing plasmid, pcDNA3.1-3ϫFlag-RTA-3=UTR, also bears the full 3=UTR sequences as described previously (52) . The hsa-miR-1258 targeting site in the RTA 3=UTR was identified with target prediction software RNAhybrid and RNA22. Mutation of the putative hsa-miR-1258 binding site, S, from the RTA 3=UTR was performed by site-directed mutagenesis using primers 5=-GAT GCG GCG AGA TTG GAG GCA CAT AAG G-3= and 5=-GAA ACA TAG TTG TGC ATC CTT TTC TTC TAA TGC C-3=. The plasmid pEGFP-N2 was used to monitor the efficiency of transfection.
Antibodies and reagents. Anti-KSHV LANA ORF73 (53) rat monoclonal antibody (MAb), anti-KSHV ORF59 (clone 11D1; IgG2b), mouse MAb, and anti-KSHV vIL-6 rabbit polyclonal antibody (PAb) were from Advanced Biotechnologies, Inc. (Columbia, MD). Anti-Flag M2 rabbit MAb was from Cell Signaling Technology (Beverly, MA). Anti-KSHV RTA peptide antibodies were generated by immunization of rabbits with two RTA peptides as previously described (47) . Horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit IgG, as well as mouse MAbs against ␤-actin, ␣-tubulin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which were used to monitor sample loading, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 12-O-Tetradecanoylphorbol-13-acetate (TPA; 20 ng/ml) was obtained from Sigma (St. Louis, MO, USA). HIV-1 Nef protein (His tag; soluble Nef) was from Abcam (Cambridge, MA). 4=,6=-Diamidino-2-phenylindole (DAPI) was purchased from Beyotime Institute of Biotechnology (China).
RT-qPCR. The sequences of specific primers and probes of real-time quantitative reverse transcription-PCR (RT-qPCR) for KSHV RTA, ORF26, and LANA genes were described previously (54) and are listed in Table 1 . Real-time quantification of miRNAs was performed by stem-loop RT-qPCR (52) . All of the reactions were run in triplicate. The primers used in RT-qPCR are listed in Table 1 . In this study, all experiments in PEL cells using soluble Nef were performed without TPA treatment. For the ectopic expression of Nef experiments, PEL cells were transfected with pCI-neo or pNef for 12 h and treated with TPA for another series of time points.
RT-PCR. RT-PCR was performed as previously described (54) . Primers for amplifying KSHV T1.1, vIL-6, ORF57, ORF26 (also known as KS330), and ␤-actin were described previously (54) . Primers for amplifying HIV-1 Nef are listed in Table 1 .
Western blot analysis.
Western blotting was performed as previously described (54) . To detect KSHV latent nuclear antigen ORF73, nuclear extracts of cells were prepared with an extraction kit (Active Motif, Tokyo, Japan). Protein blottings were visualized with enhanced chemiluminescence reagents (Cell Signaling Technology) according to the manufacturer's instructions. Protein amounts were determined by densitometry analysis using Scion Image software (Scion Corporation, Frederick, MD). Data shown were repeated at least three times to confirm the results.
Immunofluorescence assay (IFA). After transfection of BCBL-1 or BC-3 cells with pCI-neo, pNef, miRNA mimics, or suppressors, cells (10 7 / ml) were washed and smeared on chamber slides. Slides were incubated with the anti-KSHV ORF59 mouse MAb at 1:100 dilution. Alexa Fluor 568 (Invitrogen)-conjugated goat anti-mouse antibody (1:200 dilution) was used as a secondary antibody to detect the specific signal. The cells were counterstained with DAPI. Images were observed and recorded with a Zeiss Axiovert 200 M epifluorescence microscope (Carl Zeiss, Inc.). To calculate the percentage of ORF59-positive cells, photographs of at least 10 unique fields were taken for each slide, and the numbers of positive cells were counted.
Real-time DNA-PCR analysis for viral genome copy number. To determine whether Nef can repress KSHV replication and reduce the production of viral progeny, we transfected PEL cells with pNef or pCI-neo. At 12 h posttransfection, cells were induced with TPA at a concentration of 20 ng/ml for 36 h at 37°C under 5% CO 2 . KSHV virions were pelleted and concentrated in three steps. First, induced cell cultures were centrifuged for 5 min at 4,000 rpm, and supernatants were transferred to fresh tubes, centrifuged for 30 min at 4, 000 rpm, and finally filtered through a 0.45-m-pore-size membrane. KSHV virions were then pelleted from these cell-free supernatants by ultracentrifugation for 2 h at 15,000 rpm. Viral pellets were resuspended in 1/30 of the original volume in RPMI 1640 without fetal calf serum (FCS) and then divided into two parts. The first part was treated with DNase and proteinase K (10 mg/ml) before viral DNA extraction (55) . Real-time DNA-PCR was carried out on viral DNA extracted essentially as described previously (49) . The KSHV ORF26 gene cloned in pcDNA3.1 (Invitrogen) was used to generate the standard curve. RT-qPCR F, 5=-GCG CAA GAT GAC AAG GGT AAG-3= R, 5=-CGA GAG GCC GAC GAA GC-3= KSHV ORF26
RT-qPCR F, 5=-AGC CGA AAG GAT TCC ACC AT-3= R, 5=-GCT GCG GCA CGA CCA T-3= KSHV ORF57
RT-qPCR F, 5=-TGG CGA GGT CAA GCT TAA CTT C-3= R, 5=-CCC CTG GCC TGT AGT ATT CCA-3= KSHV ORF59
RT-qPCR F, 5=-TTG GCA CTC CAA CGA AAT ATT AGA A-3= R, 5=-CGG GAA CCT TTT GCG AAG A-3= KSHV ORF21
RT-qPCR F, 5=-CGT AGC CGA CGC GGA TAA-3= R, 5=-TGC CTG TAG ATT TCG GTC CAC-3= KSHV PAN RT-qPCR F, 5=-GCC GCT TCT GGT TTT CAT TG-3= R, 5=-TTG CCA AAA GCG ACG CA-3= KSHV LANA RT-qPCR F, 5=-CCG AGG ACG AAA TGG AAG TG-3= R, 5=-GGT GAT GTT CTG AGT ACA TAG CGG-3= ␤-actin RT-qPCR F, 5=-TTG CCG ACA GGA TGC AGA AGG A-3= R, 5=-AGG TGG ACA GCG AGG CCA GGA T-3= U6 snRNA RT U6, 5=-CGC TTC ACG AAT TTG CGT GTC AT-3= hsa-miR-1258 RT hsa-miR-1258, 5=-GTC GTA TCC AGT GCG TGT CGT GGA GTC GGC AAT TGC ACT GGA TAC GAC TTC CAC G-3= U6 snRNA PCR U6 F, 5=-GCT TCG GCA GCA CAT ATA CTA AAA T-3= U6 R, 5=-CGC TTC ACG AAT TTG CGT GTC AT-3= hsa-miR-1258 PCR hsa-miR-1258 GSP, 5=-GGG GAG TTA GGA TTA GGT C-3= hsa-miR-1258 R, 5=-TGC GTG TCG TGG AGT C-3=
The second portion of viral pellets was used to infect HEK293 cells as described below. Induction and analysis of infectious virus progeny. The second portion of KSHV pelleted virions was used to determine the titer of infectious virus progeny. One ml of inoculum (which equals 30 ml of supernatant) was added to HEK293 cells that have been shown previously to be permissive cells for KSHV infection (56) . After 18 h of infection, the total RNA was isolated from infected cells. RT-qPCR then was performed to quantify the expression of ORF26 mRNA. Simultaneously, the total protein was also isolated, and Western blotting was performed to detect KSHV vIL-6 (55).
Apoptosis assay. Apoptotic cells were detected by propidium iodide (PI) staining and with a fluorescein isothiocyanate (FITC)-annexin V apoptosis detection kit (BD Biosciences, San Jose, CA) according to the manufacturer's instructions.
Proliferation assay. BCBL-1 cells were plated into each well at 1 ϫ 10 6 to ϳ3 ϫ 10 6 cells per well of the 12-well plates and cultured for 0, 24, 48, or 72 h. Cells from each well were counted daily by traditional trypan blue staining in quadruplicate. Experiments were performed in duplicate and were repeated three times.
Luciferase reporter assay. 293T cells (1 ϫ 10 5 ) were transfected with 100 nmol/liter of miRNA mimic, 400 ng of reporter DNA, and 20 ng Renilla vector pRL-TK (Promega) and then harvested at 48 h posttransfection. Relative luciferase activity was assayed using the Promega dualluciferase reporter assay system. All data points were the averages of results from at least three independent transfections. miRNA microarray analysis. Total RNA from BCBL-1 cells transfected with pCI-neo or pNef for 72 h was isolated with TRIzol reagent (Invitrogen), and the miRNA fraction was further purified using a mirVana miRNA isolation kit (Ambion, Austin, TX). The isolated miRNAs from the two parallel transfected cells were then labeled with Hy3 using the miRCURY array labeling kit (Exiqon, Vedbaek, Denmark) and hybridized with miRCURY locked nucleic acid (LNA) microRNA arrays (v 8.0; Exiqon). Microarray images were acquired using a Genepix 4000B scanner (Axon Instruments, Union City, CA) and processed and analyzed with Genepix Pro 6.0 software (Axon Instruments).
miRNA mimics and suppressors. The synthetic hsa-miR-1258 mimic and miRNA negative-control mimic were obtained from Shanghai GenePharma Company (Shanghai, China). This miRNA mimic's sequence is shown in Table 2 . miRCURY LNA miRNA suppressor was obtained from Exiqon (Vedbaek, Denmark). Oligonucleotide suppressors designed for miRNAs were hsa-miR-1258 (5=-TCC ACG ACC TAA TCC TAA C-3=) and a scrambled control (5=-GTG TAA CAC GTC TAT ACG CCC A-3=). hsa-miR-1258 and the LNA oligonucleotide were transfected into PEL cells to simulate and suppress, respectively, the function of miR-1258.
RESULTS

Soluble Nef protein inhibits KSHV lytic replication following internalization into PEL cells.
Since Nef can regulate cellular functions, including induction of apoptosis (57), we examined the effect of soluble Nef protein on BCBL-1 cells. Cells were exposed to a recombinant myristoylated Nef (soluble Nef) protein that resembled native Nef at 0, 1, 10, 100, and 1,000 ng/ml for 24 h and examined for apoptosis. We found that soluble Nef protein did not induce apoptosis in BCBL-1 cells even at concentrations up to 10-fold greater than those found in serum samples from HIVinfected patients (1 to 10 ng/ml) (see Fig. S1A and B in the supplemental material).
Uninduced PEL cells are latently infected by KSHV; however, they often have low levels of lytic activities because of spontaneous viral lytic replication in these cells (58) . To determine the effect of soluble Nef protein on KSHV replication, we examined the production of viral particles upon exposure of the PEL cells to soluble Nef. As shown in Fig. 1A , Nef protein inhibited the production of KSHV viral particles in a dose-dependent manner in uninduced PEL cell lines, including BCBL-1, BC-3, and JSC-1.
It has been reported that Nef protein can be internalized by B cells both in vivo and in vitro (26) . Therefore, we determined if the soluble Nef protein was internalized by the PEL cells. Based on the results described above and those of previous studies (22, (25) (26) (27) , we chose Nef protein at concentrations of 1, 10, and 100 ng/ml for these experiments. By staining for Nef protein in BCBL-1 cells exposed to soluble Nef protein, we observed Nef protein internalization at as early as 6 h postincubation, and it continued to increase over time (Fig. 1B) . At 72 h postincubation, over 60% of BCBL-1 cells were positive for the Nef protein (data not shown). Internalized Nef protein was detected in the cytosol and perinuclear area (Fig. 1B) . To confirm that the internalized Nef regulated KSHV lytic replication in uninduced BCBL-1 cells, RT-qPCR was performed to analyze the expression of KSHV lytic genes following incubation of soluble Nef protein with BCBL-1 cells. The results showed that soluble Nef protein not only decreased the expression of all transcripts of KSHV lytic genes examined, including RTA, ORF59, ORF57, ORF26, and ORF21, as well as the PAN RNA, but also induced the expression of latent LANA transcript (Fig. 1C) . To ensure that the effect of Nef protein on the expression of KSHV transcripts was not restricted to BCBL-1 cells, the same experiments were performed in BC-3 cells. Results similar to those for BCBL-1 cells were also observed in BC-3 cells (Fig.  1C) . To examine whether inhibition of KSHV lytic transcripts by the Nef protein resulted in the repression of lytic cycle proteins, Western blot analysis was performed to examine the expression of KSHV lytic proteins. As shown in Fig. 1D , the levels of KSHV lytic proteins RTA and vIL-6 were markedly decreased in cells incubated with soluble Nef protein. Consistent with the RT-qPCR results, soluble Nef also dramatically induced the expression of latent LANA protein in BCBL-1 cells (Fig. 1D) .
Together, these data indicate that soluble Nef protein can be efficiently internalized into PEL cells, and as a result of Nef protein internalization, the KSHV spontaneous lytic replication program was inhibited.
Ectopically expressed Nef inhibits KSHV lytic replication. It has been shown that KSHV can be robustly reactivated into higher levels of lytic replication by chemical inducers, such as TPA, in PEL cells. Since we have observed an inhibitory effect of the Nef protein on KSHV spontaneous lytic replication, we further deter- to determine the optimal concentration of the plasmid expressing the Nef protein. BCBL-1 cells transfected with 0.4, 0.8, 1.6, and 3.2 g/ml of either pNef plasmid DNA or vector control pCI-neo had similar apoptotic rates (see Fig. S2A and B in the supplemental material). Importantly, similar to the inhibitory effect of the soluble Nef protein on KSHV spontaneous lytic replication, TPAinduced KSHV reactivation was inhibited following the transfection of pNef in a dose-dependent fashion ( Fig. 2A and B) . A 50% of inhibitory effect was observed when 0.8 g/ml plasmid DNA was used for the transfection, and it further increased to 60% when 1.6 and 3.2 g/ml plasmid DNA were used. Therefore, we chose 1.6 g/ml plasmid DNA for the subsequent experiments.
To further confirm that ectopic expression of Nef regulated KSHV lytic replication, we examined the expression of KSHV transcripts following the expression of Nef by RT-qPCR. Similar to the results for soluble Nef protein, ectopic expression of Nef in PEL cells not only reduced the expression of KSHV lytic transcripts, including RTA, ORF26, T1.1, vIL-6, and ORF57 ( Fig. 2C ; also see Fig. S3A in the supplemental material), but also induced the expression of latent LANA transcript (Fig. 2C) . Similar results were also observed in Vero cells infected with a KSHV recombinant virus, Bac36 (59) (Fig. 2C) . In Vero cells infected by another KSHV recombinant virus, rKSHV.219, in which the expression of a red fluorescent protein (RFP) is controlled by the KSHV lytic promoter of the PAN RNA (60), expression of pNef also significantly reduced the number of RFP-positive cells (see Fig. S3B in the supplemental material). Western blot analysis was performed to detect KSHV lytic proteins in BCBL-1 cells. As shown in Fig.  2D , the expression of both RTA and vIL-6 proteins was markedly decreased in Nef-expressing cells from 24 to 96 h following TPA induction. We also found that the expression of LANA was consistently increased in pNef-transfected BCBL-1 cells compared to that of pCI-neo-transfected cells (Fig. 2D) . Consistent with the Western blotting results, expression of Nef reduced the percentages of cells expressing the delayed early lytic protein ORF59 by 3.53-and 3.18-fold in TPA-induced BCBL-1 and BC-3 cells, respectively ( Fig. 2E and F) . We further performed real-time DNA-PCR to quantify the amount of viral genome in supernatants from Nef-expressing BCBL-1 cells. As shown in Fig. 3A , the KSHV viral genome copy number was 3.9-fold lower in pNef-transfected BCBL-1 cells. This result indicated that ectopic expression of Nef in BCBL-1 cells significantly reduced the production of viral particles. To confirm that these viral particles were infectious, we infected HEK293 cells with the supernatants and isolated the total RNA at 18 h postinfection. RT-qPCR demonstrated that KSHV ORF26 expression in HEK293 cells infected with the supernatants from pNef-transfected BCBL-1 cells was decreased 2.06-fold compared with that of pCI-neo-transfected BCBL-1 cells (Fig. 3B) . Western blot analysis showed that HEK293 cells infected with the supernatants from pNef-transfected BCBL-1 cells produced less vIL-6 than those inoculated with supernatants from vector-transfected BCBL-1 cells (Fig. 3C) . Collectively, these data suggest that ectopic expression of Nef inhibits TPA-induced KSHV reactivation.
Screening and validation of hsa-miR-1258, which targets RTA 3=UTR. MicroRNAs have been implicated in differentiation, apoptosis, proliferation, and diseases such as cancer. In fact, both viral and cellular microRNAs have been shown to regulate KSHV latency (52, (61) (62) (63) (64) (65) . Thus, we considered that microRNAs also mediate Nef suppression of KSHV lytic replication. To determine whether cellular miRNAs were involved in Nef-mediated KSHV latency, we examined the effect of Nef on the expression of cellular miRNAs using miRNA microarray. Among the cellular miRNAs that were altered, 99 of them were upregulated by Nef. We hypothesized that some of these miRNAs regulate KSHV lytic replication. Because the lytic switch protein RTA is considered to be the master regulator of the KSHV replication/latency program, bioinformatics prediction analysis, including RNAhybrid and RNA22 prediction software, combined with results of miRNA microarray identified five Nef-upregulated miRNAs that had putative targeting sites in the RTA 3=UTR (Fig. 4A) . A luciferase reporter assay using RTA 3=UTR luciferase reporter confirmed that, of the five miRNAs, cellular hsa-miR-1258 significantly inhibited the RTA 3=UTR reporter activity. KSHV microRNAs miR-K7, miR-K5, and miR-K9*, which have previously been shown to target RTA, also inhibited the RTA 3=UTR reporter activity (61-63) (Fig. 4B) . hsa-miR-1258 inhibited the reporter activity of the pGL3-RTA 3=UTR but not the control reporter pGL3 in a dosedependent manner (Fig. 4C and D) . RT-qPCR showed that the expression levels of hsa-miR-1258 were increased in both soluble Nef-incubated and pNef-transfected BCBL-1 cells in a dose-dependent manner (Fig. 4E) , which was consistent with the inhibitory effect of Nef on KSHV replication (Fig. 1 to 3) . Furthermore, TPA treatment has no effect on Nef induction of hsa-miR-1258 (see Fig. S4 in the supplemental material).
To directly assess the effect of hsa-miR-1258 on RTA expression, we transiently cotransfected an hsa-miR-1258 mimic together with an RTA expression plasmid under the control of the RTA 3=UTR, pcDNA3.1-3ϫFlag-RTA-3=UTR, into 293T cells. A GFP expression plasmid, pEGFP-N2, was included to calibrate the transfection efficacy. Western blotting indicated that hsa-miR-1258 strongly inhibited the expression of RTA in a dose-dependent manner (Fig. 4F) .
The interaction of an miRNA with its target is primarily mediated by a 6-to 7-bp seed sequence at the 5= end of the miRNA. Bioinformatics analysis identified one putative hsa-miR-1258 binding site (S) in the RTA 3=UTR (Fig. 4G) . Mutation of the putative binding site abolished the inhibitory effect of hsa-miR-1258 on the RTA 3=UTR, as shown in the reporter assay and by Western blotting for the RTA protein ( Fig. 4H and I) . As expected, a mutant mimic lacking the seed sequences also failed to inhibit the RTA 3=UTR (Fig. 4H and I) . However, because the mutant mimic was designed to match the 3=UTR mutation, it exhibited a strong inhibitory effect both in the reporter assay and by Western blot analysis ( Fig. 4H and I ). These results indicate that hsa-miR-1258 directly targets the RTA 3=UTR. hsa-miR-1258 enhances Nef inhibition of KSHV lytic replication. Western blotting was performed to confirm whether hsamiR-1258 was involved in Nef-mediated inhibition of KSHV replication by targeting RTA in PEL cells. Transfection of the hsamiR-1258 mimic enhanced the inhibitory effect of pNef on the expression of RTA and vIL-6 proteins in both BCBL-1 and BC-3 cells (Fig. 5A) . IFA showed that BCBL-1 cells cotransfected with the hsa-miR-1258 mimic had 2.01-fold less ORF59-positive cells than those transfected with the scrambled mimic ( Fig. 5B and C) . Similar results were observed with the KSHV late lytic protein minor capsid protein, ORF26 (see Fig. S5A and B in the supplemental material). Consistent with the reduced expression of KSHV lytic genes, hsa-miR-1258 mimic decreased KSHV viral genome copy number in the supernatants from Nef-transfected BCBL-1 and BC-3 cell cultures by 5.44-and 2.19-fold, respectively (Fig. 5D) .
KSHV lytic replication causes the shutdown of host gene expression and decreases cell growth. Consistent with the inhibitory effect on KSHV lytic replication, Nef increased cell proliferation, which was further enhanced by the hsa-miR-1258 mimic (Fig. 5E) . Similar results were also observed in cells treated with soluble Nef protein. hsa-miR-1258 mimic enhanced the inhibitory effect of soluble Nef protein on the expression of RTA protein and virion release ( Fig. 5F and G) .
Suppression of hsa-miR-1258 abolishes the inhibitory effect of Nef on KSHV lytic replication. Since overexpression of hsamiR-1258 significantly enhanced Nef-mediated inhibition of KSHV replication, we tested the effect of miRNA repression on Nef-mediated inhibition of KSHV lytic replication. We inhibited the function of hsa-miR-1258 using its corresponding LNA miRNA suppressor. RT-qPCR showed that the miRNA suppressor inhibited the function of hsa-miR-1258, as expected (see Fig.  S6 in the supplemental material). As shown in Fig. 6A , the expression of RTA and vIL-6 were markedly increased in Nef-transfected BCBL-1 or BC-3 cells following the suppression of hsa-miR-1258.
ORF59-positive cells were also increased 2.91-fold in BCBL-1 cells (see Fig. S7A and B in the supplemental material). As expected, the expression of ORF26 transcripts was enhanced (see Fig. S7C and D in the supplemental material). Furthermore, suppression of hsamiR-1258 increased the production of viral particles by 2.99-and 2.19-fold in BCBL-1 and BC-3 cells, respectively (Fig. 6B) . In addition, while Nef promoted cell proliferation in BCBL-1 cells, the LNA suppressor decreased the cell growth rate (Fig. 6C) .
Meanwhile, suppression of hsa-miR-1258 reversed the inhibitor effect of soluble Nef protein on the expression of RTA protein and virion release ( Fig. 6D and E) . Significantly, transfection of the hsa-miR-1258 mimic alone was sufficient to inhibit the expression of RTA and vIL-6 proteins and the production of viral particles, while transfection with a mutant mimic had no effect ( Fig. 7A and B) . Together, these data indicated that Nef inhibited KSHV replication by upregulating hsa-miR-1258, which directly targeted RTA.
DISCUSSION
As a result of the AIDS pandemic, KS has become one of the most common cancers affecting adults and children, causing significant morbidity and mortality in many subequatorial African countries (66, 67) . Although therapeutic treatments for KS exist, none is curative. Because of the lack of an effective approach for the therapy and prevention for AIDS-KS patients, it is necessary to elucidate the pathogenesis of AIDS-related malignancies (68) . Since KSHV-infected primary endothelial cells cannot be permanently maintained in culture, they are not suitable for KSHV reactivation study. In contrast, PEL cells have been used as the model for investigating KSHV replication. In this study, we demonstrated the inhibition of KSHV replication by HIV Nef and explored the possible underlying mechanisms in PEL cells. Several novel findings were made, which could provide insight into the mechanism of KSHV latency.
Our results provide direct experimental evidence that Nef can be a potential cofactor in AIDS-KS. During the course of HIV-1 infection, normal host cells are consistently exposed to free HIV-1 viral particles and circulating soluble HIV proteins. Although not directly infected by HIV, exposure to soluble HIV proteins can have a profound effect on these cells, causing dysregulation of their gene expression and normal function. Nef is one of the earliest, most abundantly expressed and secreted viral proteins (22, 25) . Circulating Nef accumulated in B cells in vivo, and soluble Nef can be internalized by B cells in vitro (26) (27) (28) . In this study, we showed that Nef can be efficiently internalized by BCBL-1 cells. More importantly, Nef delivered in the form of soluble protein or by transfection with an expression plasmid inhibited the expression of KSHV lytic genes and production of infectious virions. Interestingly, we and others have previously revealed that both Tat and cytokines induced by HIV-1-infected cells trigger KSHV reactivation from latency, resulting in the release of progeny virions. KSHV lytic replication can facilitate the spread of the virus and initiate new infection, and it is associated with early stages of KS (11, 14, 15) . However, during latency, KSHV expresses only a limited number of viral proteins, which is an effective strategy for evading host immune surveillance and to promote tumor development (69, 70) . Indeed, in KS lesions, most of the tumor cells are latently infected by KSHV, indicating that viral latency and latent products are essential for the development of KS tumors (71) . In this regard, latent infection is critical for late stages of KS development. Our results indicate that Nef contributes to the maintenance of KSHV latency and late stages of KS development.
KSHV pathogenesis depends on the balance between viral lytic replication and latency. This balance is controlled by RTA and regulated by latent gene products, such as LANA, certain cell signaling pathways, and cellular and/or viral miRNAs (7) . KSHV encodes 12 pre-miRNAs that give rise to at least 25 different miRNAs. Among them, several miRNAs regulate viral latency by directly targeting viral genes or indirectly targeting cellular pathways (52, 61-64, 72, 73) . KSHV miRNAs also regulate diverse cellular pathways (45, 52, (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) , which might contribute to the development of KSHV-related malignancies (88) . However, how cellular miRNAs regulate KSHV genes and the viral replication program remains to be elucidated.
We have identified Nef-upregulated cellular miR-1258. Our results showed that hsa-miR-1258 mediated Nef inhibition of KSHV lytic replication by directly targeting the RTA 3=UTR. hsamiR-1258 was reported to directly target heparanase (HPSE) and suppress brain metastatic breast cancer (BMBC) (89). Of interest, the level of hsa-miR-1258 is inversely correlated with HPSE expression, enzymatic activity, and cancer cell metastatic propensity. In particular, hsa-miR-1258 has a lower level in highly aggressive BMBC cell variants than either nontumorigenic or nonmetastatic human mammary epithelial cells (89) . By using bulge-loop miRNA RT-qPCR, we detected the basal levels of hsa-miR-1258 in KSHV-infected PEL cells, including BCBL-1 and BC-3, and KSHV-negative B cells, including DG75, Louckes, and BJAB cells. Surprisingly, we found that the basal expression levels of hsa-miR-1258 in PEL cells were decreased by more than 2-fold compared to that of KSHV-negative B cells (Chun Lu, unpublished data). These data imply that the lower level of hsa-miR-1258 in malignant tumors is a common phenomenon.
In patients with AIDS-associated malignancies, such as KS, PEL, and MCD, the circulating Nef protein can be internalized by KSHV-infected cells. Internalized Nef can increase the expression of hsa-miR-1258, which can directly target KSHV RTA, resulting in the inhibition of KSHV lytic replication. Importantly, we found that hsa-miR-1258 can directly target RTA. Therefore, besides Tat protein (15) , the Nef/miR-1258/RTA axis may also contribute to the regulation of the KSHV life cycle and the pathogenesis of AIDS-related malignancies. Although the functions of human miRNAs have been extensively studied, their roles in KSHV infection and pathogenesis remain largely unexplored. hsa-miR-132 has been shown to regulate antiviral innate immunity through suppression of the p300 transcriptional coactivator during KSHV infection (90) , while KSHV vIL-6 was repressed by hsa-miR-1293 (91). Our group has recently shown that hsa-miR-498 and hsa-miR-320d are involved in herpes simplex virus 1 induction of KSHV lytic replication by targeting RTA (65) . It is expected that more human miRNAs will be discovered to regulate KSHV life cycle and mediate the pathogenesis of KSHV-associated diseases in the near future.
In summary, our results support the hypothesis that, besides viral miRNAs, cellular miRNAs also play a critical role in the establishment and/or maintenance of KSHV latent infection and contribute to the evasion of host immunity and tumor formation (45, 74, 82, 90, 92) . Nef can alter the expression of several miRNAs and induce multiple signaling pathways; thus, it can contribute to the pathogenesis of AIDS-related malignancies. Further studies will be needed to better understand how Nef upregulates hsamiR-1258 expression and whether other Nef-regulated miRNAs, particularly the downregulated miRNAs, are also involved in the regulation of the KSHV life cycle.
